OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Urticarial vasculitis	112
Giant cell arteritis: update on pathogenesis and clinical implications	66
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	59
Current approach to muscle imaging in myositis	54
Editorial introduction	51
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	44
Current views on lupus in children	43
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	34
Editorial introductions	32
Axial spondyloarthritis guidelines – aiming for maximum impact	31
The gut microbiota in spondyloarthritis: an update	30
Osteoporosis epidemiology using international cohorts	30
Optimizing reproductive health management in lupus and Sjogren's syndrome	30
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	30
Rheumatoid arthritis – the challenge of heterogeneity	28
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	26
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	25
Updates on translational and clinical research in systemic sclerosis	24
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	24
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	24
Editorial introductions	24
Ribosome dysfunction in osteoarthritis	23
Update on gout management: what is old and what is new	22
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	21
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	20

Defining and managing flares in axial spondyloarthritis	18
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	18
Editorial introductions	18
Haematopoietic stem cell transplantation in paediatric rheumatic disease	17
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	17
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	17
Editorial introduction	17
Epidemiology of myositis	17
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	16
Health inequities in the rheumatic diseases of childhood	16
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	16
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	16
Editorial introductions	15
Gout and the COVID-19 pandemic	15
Animal models of vasculitis	15
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	14
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	14
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	14
AI am the future: artificial intelligence in pediatric rheumatology	13
Editorial introductions	13
New developments related to lung complications in pediatric rheumatic disease	12
Editorial introductions	11
Insights into the molecular landscape of osteoarthritis in human tissues	11
Investigating gout flares: beyond a definition	11
Insights into origins and specificities of autoantibodies in systemic sclerosis	11
Polymyositis: does it really exist as a distinct clinical subset?	11
Biomarker discovery in psoriatic disease	11
Diagnosis and management of primary heart involvement in systemic sclerosis	11
Epidemiology of osteoarthritis: literature update 2022–2023	11
Emerging biologic therapies for systemic lupus erythematosus	11
Exploring challenges in the management and treatment of inclusion body myositis	10
The association of Behçet's syndrome with HLA-B51 as understood in 2021	10
Vasculitis and the NLRP3 inflammasome	10
Editorial introduction	10
Management of postinfectious inflammatory arthritis	10
Heart involvement in systemic sclerosis: emerging concepts	10
The contribution of endothelial cells to tissue fibrosis	9
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	9
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	9
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	9
Current management of giant cell arteritis and its complications	9
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	9
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	9
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	9
Animal models in systemic sclerosis: an update	9